Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?

Ginsberg HN, Reyes-Soffer G.

J Clin Invest. 2019 Aug 26. pii: 131333. doi: 10.1172/JCI131333. [Epub ahead of print]

2.

Nuclear envelope-localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis.

Shin JY, Hernandez-Ono A, Fedotova T, Östlund C, Lee MJ, Gibeley SB, Liang CC, Dauer WT, Ginsberg HN, Worman HJ.

J Clin Invest. 2019 Aug 13;130. pii: 129769. doi: 10.1172/JCI129769.

3.

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.

Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.

Atherosclerosis. 2019 Sep;288:85-93. doi: 10.1016/j.atherosclerosis.2019.07.008. Epub 2019 Jul 12.

4.

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.

Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.

Atherosclerosis. 2019 Sep;288:194-202. doi: 10.1016/j.atherosclerosis.2019.06.896. Epub 2019 Jun 8.

5.

Life is complicated: so is apoCIII.

Reyes-Soffer G, Ginsberg HN.

J Lipid Res. 2019 Aug;60(8):1347-1349. doi: 10.1194/jlr.C119000214. Epub 2019 Jun 25. No abstract available.

PMID:
31239286
6.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P.

Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Review.

7.

Selective Trafficking of Fatty Acids in the Liver: Add Them2 to the List of Influencers.

Ginsberg HN.

Hepatology. 2019 Aug;70(2):462-464. doi: 10.1002/hep.30800. Epub 2019 Jul 15. No abstract available.

PMID:
31155742
8.

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.

Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos RD, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ.

Cardiovasc Drugs Ther. 2019 Feb;33(1):69-76. doi: 10.1007/s10557-019-06852-6.

9.

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.

Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL.

JAMA. 2019 Jan 29;321(4):364-373. doi: 10.1001/jama.2018.20045.

10.

Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.

Reyes-Soffer G, Sztalryd C, Horenstein RB, Holleran S, Matveyenko A, Thomas T, Nandakumar R, Ngai C, Karmally W, Ginsberg HN, Ramakrishnan R, Pollin TI.

Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):63-72. doi: 10.1161/ATVBAHA.118.311476.

PMID:
30580564
11.

Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.

Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, Bessac L, Pordy R, Letierce A, Ray KK.

J Am Heart Assoc. 2018 Sep 18;7(18):e009221. doi: 10.1161/JAHA.118.009221.

12.

Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.

Nandakumar R, Matveyenko A, Thomas T, Pavlyha M, Ngai C, Holleran S, Ramakrishnan R, Ginsberg HN, Karmally W, Marcovina SM, Reyes-Soffer G.

J Lipid Res. 2018 Dec;59(12):2397-2402. doi: 10.1194/jlr.P082834. Epub 2018 Oct 7.

PMID:
30293969
13.

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies.

Ginsberg HN, Farnier M, Robinson JG, Cannon CP, Sattar N, Baccara-Dinet MT, Letierce A, Bujas-Bobanovic M, Louie MJ, Colhoun HM.

Diabetes Ther. 2018 Jun;9(3):1317-1334. doi: 10.1007/s13300-018-0439-8. Epub 2018 May 19.

14.

Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2018 Jul 14;39(27):2526-2539. doi: 10.1093/eurheartj/ehy182.

15.

γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.

Kim K, Goldberg IJ, Graham MJ, Sundaram M, Bertaggia E, Lee SX, Qiang L, Haeusler RA, Metzger D, Chambon P, Yao Z, Ginsberg HN, Pajvani UB.

Cell Metab. 2018 Apr 3;27(4):816-827.e4. doi: 10.1016/j.cmet.2018.02.010. Epub 2018 Mar 22.

16.

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.

Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN.

Diabetes Obes Metab. 2018 Jul;20(7):1632-1641. doi: 10.1111/dom.13273. Epub 2018 Mar 25.

17.

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.

Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC.

Diabetes Care. 2018 Jun;41(6):1244-1250. doi: 10.2337/dc17-0968. Epub 2018 Feb 22.

PMID:
29472432
18.

FoxO transcription factors are required for hepatic HDL cholesterol clearance.

Lee SX, Heine M, Schlein C, Ramakrishnan R, Liu J, Belnavis G, Haimi I, Fischer AW, Ginsberg HN, Heeren J, Rinninger F, Haeusler RA.

J Clin Invest. 2018 Apr 2;128(4):1615-1626. doi: 10.1172/JCI94230. Epub 2018 Mar 19.

19.

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L.

J Am Coll Cardiol. 2018 Jan 16;71(2):177-192. doi: 10.1016/j.jacc.2017.11.014. Review.

20.

No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.

Harvey PD, Sabbagh MN, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, Mandel J, Farnier M.

Eur Heart J. 2018 Feb 1;39(5):374-381. doi: 10.1093/eurheartj/ehx661.

21.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.

Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS.

JAMA. 2017 Sep 12;318(10):947-956. doi: 10.1001/jama.2017.11467.

22.

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.

Clin Pharmacol Ther. 2018 Apr;103(4):712-721. doi: 10.1002/cpt.798. Epub 2017 Nov 3.

23.

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.

Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, Jumes P, Wagner JA, Hubbard B, Previs SF, Roddy T, Johnson-Levonas AO, Gutstein DE, Marcovina SM, Rader DJ, Ginsberg HN, Millar JS, Reyes-Soffer G.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1770-1775. doi: 10.1161/ATVBAHA.117.309549. Epub 2017 Jul 20.

24.

The metabolism of lipoprotein (a): an ever-evolving story.

Reyes-Soffer G, Ginsberg HN, Ramakrishnan R.

J Lipid Res. 2017 Sep;58(9):1756-1764. doi: 10.1194/jlr.R077693. Epub 2017 Jul 18. Review.

25.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL.

Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144. Review.

26.

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.

Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G.

J Lipid Res. 2017 Jun;58(6):1214-1220. doi: 10.1194/jlr.M074880. Epub 2017 Mar 17.

27.

Chronic alcohol consumption decreases brown adipose tissue mass and disrupts thermoregulation: a possible role for altered retinoid signaling.

Blaner WS, Gao MA, Jiang H, Dalmer TR, Hu XJ, Ginsberg HN, Clugston RD.

Sci Rep. 2017 Mar 6;7:43474. doi: 10.1038/srep43474.

28.

Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study.

Kats D, Sharrett AR, Ginsberg HN, Nambi V, Ballantyne CM, Hoogeveen RC, Heiss G.

BMJ Open Diabetes Res Care. 2017 Feb 1;5(1):e000335. doi: 10.1136/bmjdrc-2016-000335. eCollection 2017.

29.

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.

Khavandi M, Duarte F, Ginsberg HN, Reyes-Soffer G.

Curr Cardiol Rep. 2017 Jan;19(1):7. doi: 10.1007/s11886-017-0818-1. Review.

30.

Normalization of Hepatic Homeostasis in the Npc1nmf164 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat.

Munkacsi AB, Hammond N, Schneider RT, Senanayake DS, Higaki K, Lagutin K, Bloor SJ, Ory DS, Maue RA, Chen FW, Hernandez-Ono A, Dahlson N, Repa JJ, Ginsberg HN, Ioannou YA, Sturley SL.

J Biol Chem. 2017 Mar 17;292(11):4395-4410. doi: 10.1074/jbc.M116.770578. Epub 2016 Dec 28.

31.

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators.

JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828. Erratum in: JAMA Cardiol. 2017 Apr 1;2(4):461.

32.

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN.

Circulation. 2017 Jan 24;135(4):352-362. doi: 10.1161/CIRCULATIONAHA.116.025253. Epub 2016 Dec 16.

33.

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.

Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP.

Circulation. 2016 Dec 13;134(24):1931-1943. Epub 2016 Oct 24.

34.

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.

Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E.

Cardiovasc Drugs Ther. 2016 Oct;30(5):473-483.

35.

Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis.

Conlon DM, Thomas T, Fedotova T, Hernandez-Ono A, Di Paolo G, Chan RB, Ruggles K, Gibeley S, Liu J, Ginsberg HN.

J Clin Invest. 2016 Oct 3;126(10):3852-3867. doi: 10.1172/JCI86028. Epub 2016 Sep 6.

36.

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.

Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry RR, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH.

Eur Heart J. 2016 Oct 14;37(39):2981-2989. Epub 2016 Jul 26.

37.

Impaired postprandial lipemic response in chronic kidney disease.

Saland JM, Satlin LM, Zalsos-Johnson J, Cremers S, Ginsberg HN.

Kidney Int. 2016 Jul;90(1):172-80. doi: 10.1016/j.kint.2016.02.031. Epub 2016 May 7.

38.

Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling.

Liu J, Hernandez-Ono A, Graham MJ, Galton VA, Ginsberg HN.

Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1356-66. doi: 10.1161/ATVBAHA.116.307330. Epub 2016 May 5.

39.

Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.

Leung V, Chiu YL, Kotler DP, Albu J, Zhu YS, Ham K, Engelson ES, Hammad H, Christos P, Donovan DS, Ginsberg HN, Glesby MJ.

HIV Clin Trials. 2016 Mar;17(2):55-62. doi: 10.1080/15284336.2015.1126424. Epub 2016 Feb 1.

40.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Pollan L, Tohyama J, Johnson-Levonas AO, Wagner JA, Holleran S, Obunike J, Liu Y, Ramakrishnan R, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ.

J Clin Invest. 2016 Apr 1;126(4):1603-4. doi: 10.1172/JCI87364. Epub 2016 Apr 1. No abstract available.

41.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.

Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):994-1002. doi: 10.1161/ATVBAHA.115.306680. Epub 2016 Mar 10. Erratum in: Arterioscler Thromb Vasc Biol. 2016 May;36(5):e51.

42.

Lipoprotein (a): Coming of Age at Last.

Witztum JL, Ginsberg HN.

J Lipid Res. 2016 Mar;57(3):336-9. doi: 10.1194/jlr.E066985. Epub 2016 Feb 2. Review. No abstract available.

43.

Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.

Reyes-Soffer G, Moon B, Hernandez-Ono A, Dionizovik-Dimanovski M, Jimenez J, Obunike J, Thomas T, Ngai C, Fontanez N, Donovan DS, Karmally W, Holleran S, Ramakrishnan R, Mittleman RS, Ginsberg HN.

Sci Transl Med. 2016 Jan 27;8(323):323ra12. doi: 10.1126/scitranslmed.aad2195. Erratum in: Sci Transl Med. 2016 Feb 10;8(325):325er3. Dionizovick-Dimanovski, Marija [corrected to Dionizovik-Dimanovski, Marija].

44.

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.

Chapman MJ, Stock JK, Ginsberg HN; PCSK9 Forum.

Curr Opin Lipidol. 2015 Dec;26(6):511-20. doi: 10.1097/MOL.0000000000000239. Review.

45.

Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.

Hegele RA, Gidding SS, Ginsberg HN, McPherson R, Raal FJ, Rader DJ, Robinson JG, Welty FK.

Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2269-80. doi: 10.1161/ATVBAHA.115.306442. Epub 2015 Sep 16. Review.

46.

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.

Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M.

Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.

47.

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2015 Sep 21;36(36):2425-37. doi: 10.1093/eurheartj/ehv157. Epub 2015 May 25. Review.

48.

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Pollan L, Tohyama J, Johnson-Levonas AO, Wagner JA, Holleran S, Obunike J, Liu Y, Ramakrishnan R, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ.

J Clin Invest. 2015 Jun;125(6):2510-22. doi: 10.1172/JCI80025. Epub 2015 May 11. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1603-4.

49.

[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; Avrupa Ateroskleroz Derneği Ailevi Hiperkolesterolemi Uzlaşi Paneli.

Turk Kardiyol Dern Ars. 2015 Mar;43 Suppl 1:1-14. Turkish. No abstract available.

50.

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18. Review.

Supplemental Content

Loading ...
Support Center